Rivaroxaban Precision Dosing Strategy for Real-World Atrial Fibrillation Patients

Area of Science:

• Pharmacokinetics and Pharmacodynamics
• Cardiovascular Medicine
• Nephrology

Background:

• Rivaroxaban is a direct-acting oral anticoagulant for stroke prevention in atrial fibrillation (AF).
• Current dosing guidelines (15 mg or 20 mg daily) are based on renal function but may lack precision for diverse real-world patients.
• Optimizing rivaroxaban dosage is crucial for balancing efficacy and safety.

Purpose of the Study:

• To evaluate the impact of extreme creatinine clearance (CrCl) values on rivaroxaban clearance.
• To propose more precise rivaroxaban dosing recommendations for adult AF patients.
• To establish a basis for prospective testing of new dosing strategies.

Main Methods:

• Utilized a published population pharmacokinetic model for rivaroxaban.
• Applied exposure variation limits (±20%) based on existing literature.
• Simulated rivaroxaban clearance across a wide range of CrCl values.

Main Results:

• Proposed new dosing recommendations: 10 mg once daily (CrCl 15-29 mL/min), 15 mg once daily (CrCl 30-69 mL/min), 10 mg twice daily (CrCl 70-159 mL/min), and 15 mg twice daily (CrCl 160-250 mL/min).
• These recommendations aim to improve dosing precision beyond current guidelines.
• The model suggests significant variations in rivaroxaban clearance at the extremes of renal function.

Conclusions:

• Refined dosing strategies for rivaroxaban, tailored to specific creatinine clearance ranges, are proposed.
• These recommendations necessitate prospective validation to confirm their impact on AF patient outcomes.
• Enhanced dosing precision holds potential for improved safety and efficacy in rivaroxaban therapy.